Biotech Values

[DewDiligence]

MNTA – Paul Bisaro, WPI’s CEO, said on Thursday’s CC that WPI has included no revenue from generic Lovenox in its 2009 internal budget. This is hardly surprising, but it would have been disconcerting to MNTA investors if WPI had included Lovenox revenue in its budget.

WPI will handle commercialization of Amphastar’s generic Lovenox if Amphastar’s ANDA is approved by the FDA.